Supplementary Information

Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration

Sebastian Fiedler¹, Sean R. A. Devenish¹, Alexey S. Morgunov^{1,2}, Alison Ilsley¹, Francesco Ricci¹, Marc Emmenegger³, Vasilis Kosmoliaptsis^{4,5,6}, Elitza S. Theel⁷, John R. Mills^{8,9}, Anton M. Sholukh¹⁰, Adriano Aguzzi³, Akiko Iwasaki^{11,12,13,14}, Andrew K. Lynn¹, Tuomas P. J. Knowles^{1,2,15*}

¹Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, United Kingdom

²Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom

³Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland

⁴Department of Surgery, University of Cambridge, Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom

⁵NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation, University of Cambridge, Hills Road, Cambridge CB2 0QQ, United Kingdom

⁶NIHR Cambridge Biomedical Research Centre, Hills Road, Cambridge CB2 0QQ, United Kingdom

⁷Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

⁸Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

⁹Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA

¹⁰Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

¹¹Department of Immunobiology, Yale School of Medicine, New Haven, CT 06519, USA

¹²Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA

¹³Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06511, USA

¹⁴Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

¹⁵Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Ave, Cambridge CB3 OHE, United Kingdom

*to whom correspondence should be addressed: tpjk2@cam.ac.uk

		SARS-CoV-2 variant												
Spike protein		Alpha	Beta	Gamma	Delta	Карра	Omicron (BA.1)	Omicron (BA.2)	Eta	lota	Lambda	Mu		
Domain	Region					S	hared mutati	nutations						
		L18F	L18F											
					T19R			T19I						
				P26S				P26-						
	NTD						A67V		A67V					
		H69-					H69-		H69-					
		V70-					V70-		V70-					
							T95I			T95I		T95I		
							G142-	G142-						
							V143-	V143-						
		Y144-					Y144-	Y144-	Y144-			Y144S		
							Y145D	Y145D				Y145N		
										D253G	D253N			
							G339D	G339D						
							S371L	S371F						
S1							S373P	S373P						
							S375F	S375F						
			K417N	K417T			K417N	K417N						
							N440K	N440K						
	RBD				L452R	L452R					L452Q			
							S477N	S477N						
					T478K		T478K	T478K						
			E484K	E484K		E484Q	E484A	E484A	E484K	E484K		E484K		
	SD2						Q493R	Q493R						
							Q498R	Q498R						
		N501Y	N501Y	N501Y			N501Y	N501Y				N501Y		
							Y505H	Y505H						
		D614G	D614G	D614G	D614G	D614G	D614G	D614G	D614G	D614G	D614G	D614G		
				H655Y			H655Y	H655Y						
							N679K	N679K						
		P681H			P681R	P681R	P681H	P681H				P681H		
			A701V							A701V				
							N764K	N764K						
S2							D796Y	D796Y						
					D950N							D950N		
	HR1						Q954H	Q954H						
							N969K	N969K						

Table S1. Mutations within the spike protein shared among SARS-CoV-2 variants⁴⁴.

SARS-CoV-2 variant										
Alpha	Beta	Gamma	Delta	Карра	Omicron (BA.1)	Omicron (BA.2)	Eta	Lota	Lambda	Mu
Unique mutations										
A570D	D80A	T20N	E156-	E154K	N211-	L24-	Q52R	L5F	G75V	R346K
T716I	D215G	D138Y	F157-	Q1071H	L212I	P25-	Q677H		T76I	
S982A	L241-	R190S	R158G		G446S	A27S	F888L		R246-	
D1118H	L242-	T1027I			G496S	V213G			S247-	
	A243-	V1176F			Т547К	T376A			Y248-	
					N856K	D405N			L249-	
					L981F	R408S			T250-	
									P251-	
									G252-	
									F490S	
									T859N	

Table S2. Mutations within the spike protein unique among SARS-CoV-2 variants⁴⁴.

Table S3. Summary of unpublished microfluidic antibody affinity profiling data from SARS-CoV-2 convalescent samples shown in Figure 3. Results from samples collected by Blutspendedienst (BDS) Kanton Zürich and University Hospital Zurich (CH) have been published previously in *Life Sci. Alliance* 2021, 5 (2), e202101270.

Sample source: Working reagent for anti-SARS-CoV-2 immunoglobulin, NIBSC code 21/234. National Institute for Biological Standards and Control (UK)											
		<i>K</i> ₀ (nM)			[antibody] (nM)						
antigen	best fit	lower 95% Cl	upper 95% Cl		best fit	upper 95% Cl	lower 95% Cl				
SARS-CoV-2 wt spike RBD	12.3	9.3	16.4		110	130	93.9				
SARS-CoV-2 delta spike RBD	17.5	13	24.3		119	138	98.1				
SARS-CoV-2 omicron spike RBD	30.1	23	39.9		59.3	71.7	46.4				
Sample source: Fred Hutchinson Cancer Research Center, Seattle WA, USA											
		K _D (nM)	ſ		[antibody] (nM)						
antigen	best fit	lower 95% Cl	upper 95% Cl		best fit	lower 95% Cl	upper 95% Cl				
SARS-CoV-2 wt spike RBD	11.2	3.2	26.8		246	76.7	452				
SARS-CoV-2 wt spike RBD	9.3	4.1	18.9		70.5	40.5	110				
SARS-CoV-2 wt spike RBD	6.9	3.6	12.2		676.8	597	813				
SARS-CoV-2 wt spike RBD	9.4	5.8	13.2		240	196	281				
SARS-CoV-2 wt spike RBD	17.4	12.4	23.1		495	414	583				
SARS-CoV-2 wt spike RBD	8.6	3.2	25.9		424	230	777				
SARS-CoV-2 wt spike RBD	40.4	23.5	64.9		239	161	324				
SARS-CoV-2 wt spike RBD	15.1	0.29	37.0		104	3.1	202				
SARS-CoV-2 wt spike RBD	4.5	0.01	11.2		190	67.7	349				
SARS-CoV-2 wt spike RBD	10.9	3.9	27.4		170	77.3	275				
SARS-CoV-2 wt spike RBD	9.3	0.06	28.5		71.7	22.0	127				
SARS-CoV-2 wt spike RBD	5.8	1.9	11.0		140	99.6	192				
SARS-CoV-2 wt spike RBD	25.4	11.9	60.9		249	127	400				
SARS-CoV-2 wt spike RBD	9.7	0.01	1108		9.7	0.09	1416				
SARS-CoV-2 wt spike RBD	9.4	3.4	16.1		1778	1176	2270				
SARS-CoV-2 wt spike RBD	30.7	11.8	62.5		275	146	788				
SARS-CoV-2 wt spike RBD	6.8	1.4	19.6		26.7	11.3	46				
SARS-CoV-2 wt spike RBD	48.3	1.0	278		326	4.5	804				
SARS-CoV-2 wt spike RBD	9.2	0.01	294		373	0.0	3441				
SARS-CoV-2 wt spike RBD	6.5	2.8	11.7		135	108	178				
SARS-CoV-2 wt spike RBD	51.8	20.0	124		340	103	1014				
SARS-CoV-2 wt spike RBD	16.3	10.5	24.1		297	224	383				
SARS-CoV-2 wt spike RBD	7.4	0.02	14.3		96.0	32.0	151				
SARS-CoV-2 wt spike RBD	29.2	17.2	47.7		430	241	583				
SARS-CoV-2 wt spike RBD	18.5	8.1	37.7		92.0	39.0	153				
	Sam	ple source: Mayo	Clinic, Rochester, N	ИN,	USA						

		K _D (nM)		[antibody] (nM)			
antigen	best fit	lower 95% Cl	upper 95% Cl	best fit	lower 95% Cl	upper 95% Cl	
SARS-CoV-2 wt spike RBD	0.55	0.011	1.5	2.3	1.2	5.6	
SARS-CoV-2 wt spike RBD	0.02	0.010	1.98	22.3	14.6	66.5	
SARS-CoV-2 wt spike RBD	1.0	0.013	2.8	19.4	13.1	26.2	
SARS-CoV-2 wt spike RBD	0.02	0.010	0.67	3.3	2.0	10.4	